1. Volume 25, Issue 7, Pages 1491-1500 (July 2017)
Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes 
Shoshy Mizrahy, Inbal Hazan-Halevy, Niels Dammes, Dalit Landesman-Milo, Dan Peer 
Molecular Therapy 
Volume 25, Issue 7, Pages (July 2017)
DOI: /j.ymthe
Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

2. Figure 1 RNAi Delivery Strategies Available for Lymphocytes
(A) SNALP coated with specific ligand molecules encapsulated with siRNAs. (B) Apt-siRNA conjugate. (C) Cationic polymer-based nanoparticles encapsulated with plasmid DNA and siRNAs. (D) Single-chain variable fragment (scFv)-siRNA conjugate. (E) Antibody-protamine fusion protein-siRNA conjugate.
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

3. Figure 2 Schematic Diagram of the Production Process of Targeted LNPs
Lipids including the ionizable lipid and PEG-maleimide dissolved in ethanol and siRNAs in acetate buffer are combined by the microfluidic mixer to produce malamide-functionalized LNPs. Reduced immunoglobulin Gs (IgGs) are conjugated with maleimide-functionalized LNPs to produce targeted LNPs (tLNPs). To remove unconjugated antibody, tLNPs are purified by gel filtration chromatography. mAb, monoclonal antibody.
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions